tbuckley/cabot-search huggingface dataset:
HYDRENCEPHALOCELE.
Authors: CARL BECK
Journal: JAMA (1900)

The prognosis of hydrencephalocele, formerly so extremely unfavorable, has become more promising under the auspices of asepsis, as well as under those of the Roentgen rays, which have but recently added a further element of better knowledge. As an illustration the following cases may serve: <h3>Case 1.</h3> —A boy of 5 weeks of age well nourished and otherwise normal, shows a spherical, non-pulsating tumor of the size of an orange, projecting from the nasofrontal region and sinking downward to the alæ nasi. (Fig. 1.) At birth the tumor was a trifle smaller. The family history shows nothing abnormal. The father is a German laborer, the mother was born in New York City. Both parents are anemic. The mother was a multipara—four previous children—and the confinement was normal. In connection with the question of injuries being etiological factors in the defects of development of early intrauterine life, it is interesting to
REGISTRATION OF BIRTHS.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A multi-center, open-label study to evaluate the safety and efficacy of pentostatin, cytoxan, and rituxan (PCR) in the treatment of previously untreated or treated, stage III or IV, low-grade B-Cell NHL
Authors: R. R. Mena, N. P. Christiansen, D. W. Nyman, Y. Markan, N. M. Chowhan
Journal: Journal of Clinical Oncology (2006)

7591 Background: The decision to treat indolent B-cell NHL is often based on progressive disease, worsening symptoms, and increasing hematological derangement. When treatment is indicated, these lymphoproliferative disorders are very sensitive to combination chemotherapies. Combination therapy with these agents, pentostatin (P), a purine analog, cyclophosphamide (C), a DNA alkylator, and rituximab (R), an anti-CD20 monoclonal antibody, represents a promising approach in the treatment of these patients. Most regimens have utilized fludarabine (F) as the purine analog but the myelosuppression and immunosuppression of (F) combinations frequently results in severe infections. Methods: Eligibility criteria allow previously treated and treatment-naïve patients diagnosed with low-grade stage III/IV NHL (REAL classification) to be enrolled. Treatment consisted of intravenous infusions of P (4 mg/m 2 ), C (600 mg/m 2 ), and R (375 mg/m 2 ) on day 1 of a 21-day cycle for a total of 8 cycles. Clinical evaluation was performed after cycles 2, 4, 6 and 8. Patients were stratified by disease and by prior treatment status. Results: The intent-to-treat (ITT) population consisted of 54 NHL patients (median age 65, range 30–86) who received a total of 330 cycles (median 6 per patient). The ECOG status was 0 (31%), 1 (58%) and 2 (12%). The overall objective response rate was 71% (CR 15%, Cru 13%, PR 43%). Eight grade 4 neutropenias were documented along with a single grade 4 leukopenia. There were a total of 3 deaths which occurred within 30 days of the last dose. The first death was due to a second primary, NSCLC, diagnosed after treatment began. The second death occurred in an 81 year-old female, who had achieved PR, and her death was due to CHF. The last death, due to MI/CAD, occurred in an 84 year-old woman with SD. Conclusions: This immunochemotherapeutic regimen is active in indolent Grade III/IV NHL and the incidence of significant toxicities was low. Updated trial results will be presented at the ASCO annual meeting. Future trials evaluating the use of R as maintenance therapy following this PCR regimen may also be warranted with an eye toward increasing the overall survival of patients with NHL. No significant financial relationships to disclose.
The cardiac renin-angiotensin system: its possible role in cell communication and impulse propagation
Authors: W. C De Mello
Journal: Cardiovascular Research (1995)

Journal Article The cardiac renin-angiotensin system: its possible role in cell communication and impulse propagation Get access Walmor C De Mello Walmor C De Mello Department of Pharmacology, School of Medicine, University of Puerto Rico, San Juan, Puerto Rico 00936-5067, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 29, Issue 6, June 1995, Pages 730–736, https://doi.org/10.1016/S0008-6363(96)88606-8 Published: 01 June 1995 Article history Received: 18 July 1994 Accepted: 27 January 1995 Published: 01 June 1995
Annual of the Universal Medical Sciences. A yearly report of the progress of the general sanitary sciences throughout the world.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation of Mutagenicity Testing with Salmonella typhimurium TA102 in Three Different Laboratories
Authors: W. Muller, G. Engelhart, B. Herbold, R. Jackh, R. Jung
Journal: Environmental Health Perspectives (1993)

Thirty compounds of various chemical classes were investigated for mutagenicity in a collaborative study (three laboratories) using Salmonella typhimurium TA102.With five compounds, hydrazine sulfate, phenyl- hydrazine, hydralazine, glutardialdehyde, and glyoxal, mutagenicity was detected by all laboratories.Formal- dehyde was assessed as weakly mutagenic in only one of three laboratories.The remaining 24 agents were uniformly described as nongenotoxic in TA102.In spite of the overall good qualitative agreement in the mutagenicity results between the three laboratories, some quantitive discrepancies occurred in the dose response of the mutagenic compounds.Varying inter-and intralaboratory differences in the spontaneous rate of revertants were obtained.The usefulness of the tester strain TA102 in routine mutagenicity testing is discussed.
An fMRI-Based Neurologic Signature of Physical Pain
Authors: Tor D. Wager, Lauren Y. Atlas, Martin A. Lindquist, Mathieu Roy, Choong-Wan Woo, Ethan Kross
Journal: New England Journal of Medicine (2013)

Persistent pain is measured by means of self-report, the sole reliance on which hampers diagnosis and treatment. Functional magnetic resonance imaging (fMRI) holds promise for identifying objective measures of pain, but brain measures that are sensitive and specific to physical pain have not yet been identified.In four studies involving a total of 114 participants, we developed an fMRI-based measure that predicts pain intensity at the level of the individual person. In study 1, we used machine-learning analyses to identify a pattern of fMRI activity across brain regions--a neurologic signature--that was associated with heat-induced pain. The pattern included the thalamus, the posterior and anterior insulae, the secondary somatosensory cortex, the anterior cingulate cortex, the periaqueductal gray matter, and other regions. In study 2, we tested the sensitivity and specificity of the signature to pain versus warmth in a new sample. In study 3, we assessed specificity relative to social pain, which activates many of the same brain regions as physical pain. In study 4, we assessed the responsiveness of the measure to the analgesic agent remifentanil.In study 1, the neurologic signature showed sensitivity and specificity of 94% or more (95% confidence interval [CI], 89 to 98) in discriminating painful heat from nonpainful warmth, pain anticipation, and pain recall. In study 2, the signature discriminated between painful heat and nonpainful warmth with 93% sensitivity and specificity (95% CI, 84 to 100). In study 3, it discriminated between physical pain and social pain with 85% sensitivity (95% CI, 76 to 94) and 73% specificity (95% CI, 61 to 84) and with 95% sensitivity and specificity in a forced-choice test of which of two conditions was more painful. In study 4, the strength of the signature response was substantially reduced when remifentanil was administered.It is possible to use fMRI to assess pain elicited by noxious heat in healthy persons. Future studies are needed to assess whether the signature predicts clinical pain. (Funded by the National Institute on Drug Abuse and others.).
Patentwatch
Journal: Nature Reviews Drug Discovery (2006)

Heart drug double trouble for AZThe US District Court for the East District of Missouri has ruled that two of AstraZeneca's key patents for its blockbuster angina drug extended-release metoprolol succinate (Toprol-XL) are invalid.The ruling comes after AZ sued generic drugmakers KV Pharmaceutical Co., Andrx Pharmaceuticals and Eon Labs Manufacturing after they filed Abbreviated New Drug Applications (ANDAs) for generic versions of the drug.
Obituaries
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Distress Management
Authors: Jimmie C Holland, Barbara Andersen, William S Breitbart, Bruce Compas, Moreen M Dudley, Stewart Fleishman, Caryl D Fulcher, Donna B Greenberg, Carl B Greiner, George F Handzo, Laura Hoofring, Paul B Jacobsen, Sara J Knight, Kate Learson, Michael H Levy, Matthew J Loscalzo, Sharon Manne, Randi McAllister-Black, Michelle B Riba, Kristin Roper, Alan D Valentine, Lynne I Wagner, Michael A Zevon
Journal: Journal of the National Comprehensive Cancer Network (2010)

In the United States, a total of 1,479,350 new cancer cases and 562,340 deaths from cancer were estimated to occur in 2009. 1 All patients experience some level of distress associated with the diagnosis and treatment of cancer at all stages of the disease.Surveys have found that 20% to 40% of patients with newly diagnosed and recurrent cancer show a significant level of distress. 2However, fewer than 10% are actually identified and referred for psychosocial help. 3any cancer patients who are in need of psychosocial care are not able to get the help they need due to the under recognition of patient's psychological needs by the primary oncology team and lack of knowledge of community resources.The need is particularly acute in community oncology practices that
RE: Elevated Bladder Cancer in Northern New England: The Role of Drinking Water and Arsenic
Authors: Stella Koutros, Petra Lenz, Stephen M Hewitt, Masatoshi Kida, Michael Jones, Alan R Schned, Dalsu Baris, Ruth Pfeiffer, Molly Schwenn, Alison Johnson, Margaret R Karagas, Montserrat Garcia-Closas, Nathaniel Rothman, Lee E Moore, Debra T Silverman
Journal: JNCI Journal of the National Cancer Institute (2018)
CAUSES OF CHANGES IN THE CIRCULATION OF THE FEET
Journal: JAMA (1929)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3543: Clinical whole genome sequencing at scale
Authors: Alyssa MacBeth, Tera Bowers, Betty Woolf, Maegan Harden, Niall Lennon, Stacey Gabriel
Journal: Cancer Research (2019)

Abstract Whole genome sequencing (WGS) offers the greatest potential to comprehensively and accurately identify all forms of human genetic variation. The accessibility of WGS data for diagnostic use has increased due to cost reductions in recent years, driving the need for a high quality, clinically validated offering. Our platform has completed an extensive benchmarking study of the Illumina PCR-free whole genome pipeline to establish clinical validity for the end-to-end laboratory, analytical, and computational processes. Our benchmarking study is comprehensive in nature, including measuring the precision, robustness, limits of detection for variant classes, and contamination estimates. A cohort of well-characterized reference controls and clinical samples with previously identified pathogenic variants were used to establish the performance characteristics of our clinical WGS test, which at 30X coverage has &amp;gt;99% analytical sensitivity for SNVs and &amp;gt;98% analytical sensitivity for small insertions and deletions. Our platform is capable of operating at a scale that supports applications from individual clinics (cancer and medical genetics related applications) as well as large scale ambitious collaborative projects such as the All Of Us program which aims to generate clinical grade whole genome variant calls for 1 million healthy research participants. Citation Format: Alyssa MacBeth, Tera Bowers, Betty Woolf, Maegan Harden, Niall Lennon, Stacey Gabriel. Clinical whole genome sequencing at scale [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3543.
'Brain death' and organ retrieval
Authors: John J. Oro
Journal: JAMA (1989)

<h3>To the Editor.—</h3> In their editorial, Dr Wikler and Mr Weisbard<sup>1</sup>suggest that the reason for the confusion regarding the determination of "brain death" is due to conceptual confusion; they propose a change in the definition of brain death that would allow it to be declared when higher cortical functions are lost regardless of brain-stem function. Such a redefinition undoubtedly would increase the number of organs available for transplantation. While this is a worthwhile goal, the physician making the determination should keep in mind that the fundamental reason for the concept of brain death is patient centered and based on an understanding of the nature of man. As stated by Veith et al,<sup>2</sup>"In the circumstance of brain death, neither a human being nor person any longer exists... it is an affront to the individual person or that person's memory to treat a human being who has irreversibly
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone
Authors: Brent A. Neuschwander-Tetri, Elizabeth M. Brunt, Kent R. Wehmeier, Dana Oliver, Bruce R. Bacon
Journal: Hepatology (2003)

Insulin resistance (IR) commonly is associated with nonalcoholic steatohepatitis (NASH). To establish whether IR causes NASH, this study was undertaken to determine if improving IR would improve the histologic features that define NASH. Thirty adults with prior biopsy evidence of NASH were enrolled to receive rosiglitazone, 4 mg twice daily for 48 weeks. All patients were overweight (body mass index [BMI] &gt; 25 kg/m 2 ) and 23% were severely obese (BMI &gt; 35 kg/m 2 ); 50% had impaired glucose tolerance or diabetes. Liver biopsy specimens were obtained before beginning treatment and at treatment completion. Twenty–six patients had posttreatment biopsies; of these, 22 had initial protocol liver biopsies that met published criteria for NASH on subsequent blinded evaluation. Within this initial NASH group, the mean global necroinflammatory score significantly improved with treatment and biopsies of 10 patients (45%) no longer met published criteria for NASH after treatment. Significant improvement in hepatocellular ballooning and zone 3 perisinusoidal fibrosis also occurred. Five patients withdrew early; the 25 patients completing 48 weeks of treatment had significantly improved insulin sensitivity and mean serum alanine aminotransferase (ALT) levels (104 initially, 42 U/L at the end of treatment). Adverse effects led to withdrawal of 3 patients (10%). Weight gain occurred in 67% of patients and the median weight increase was 7.3%. Within 6 months of completing treatment, liver enzyme levels had increased to near pretreatment levels. In conclusion, improving insulin sensitivity with rosiglitazone resulted in improved histologic markers of NASH, an observation suggesting that insulin resistance contributes to its development and that improving insulin sensitivity may be important in treating this liver disease.
36. Transplantation of SM/C-2.6+ Satellite Cells Transduced with Micro-Dystrophin CS1 cDNA by Lentiviral Vector into mdx Mice
Authors: Madoka Ikemoto, So-ichiro Fukada, Akiyoshi Uezumi, Satoru Masuda, Ampong Beryl Nyamekye, Hiroyuki Miyoshi, Hiroshi Yamamoto, Yuko Miyagoe-Suzuki, Shin'ichi Takeda
Journal: Molecular Therapy (2006)
Public Health and Preventive Medicine
Authors: William H. Foege
Journal: JAMA (1985)

The J- he health of people continues to improve in the United States. Currently, the life expectancy at birth is 75 years of age. Life expectancy for white Americans has increased by about three months per year since 1970; the increase for black Americans has been about 4.5 months per year.<sup>1</sup>Although infant mortality rates have continued to decline to an all-time low of less than 11 deaths per 1,000 live births, concern has been expressed that the United States is not realizing its potential to decrease infant mortality to the level demonstrated in some countries.<sup>1</sup> In contrast to the heartening improvements, about two thirds of all deaths in this country are premature, given our present medical knowledge, and about two thirds of all years of life lost before age 65 are theoretically preventable given our current capabilities (<i>Closing the Gap: National Health Policy Consultation</i>. Atlanta, The Carter
The Race Against Time
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal